BIOAVAILABILITY80–100% for immediate-release oral tablets; enteric-coated formulations have delayed and sometimes incomplete absorption (bioavailability can be reduced to 50–70% depending on gastric pH and transit time).
ADMIN ROUTEOral, Rectal
FOOD EFFECTFood delays the absorption of immediate-release aspirin and significantly blunts the peak plasma concentration (Cmax) without substantially altering the total extent of absorption (AUC) for standard tablets. For enteric-coated formulations, food can unpredictably delay gastric emptying, causing the tablet to remain in the stomach where the acidic environment prevents the coating from dissolving, leading to erratic absorption or the tablet passing intact into the intestines later. Clinically, taking aspirin with food or milk is universally recommended to mitigate direct gastric mucosal irritation, even though the systemic antiplatelet effect is preserved.
PROTEIN BINDINGAspirin is weakly bound to plasma proteins. Its primary active metabolite, salicylic acid, is highly protein-bound (80–90%), primarily to albumin. This high binding affinity makes salicylate susceptible to displacement interactions with other highly protein-bound drugs (e.g., warfarin, methotrexate, sulfonylureas), potentially increasing the free, active fraction of those drugs and precipitating toxicity.
VOLUME OF DISTRIBUTIONSalicylic acid: 0.15–0.20 L/kg (approx. 10–14 L in adults) — indicating distribution primarily within the extracellular fluid and total body water, with limited extensive tissue binding.
HALF-LIFE (t½)Aspirin (parent drug): 15–20 minutes (rapidly hydrolyzed). Salicylic acid (active metabolite): dose-dependent — 2–3 hours at low antiplatelet doses (≤300 mg), extending to 4–6 hours at analgesic doses (1 g), and up to 15–30 hours at toxic or high anti-inflammatory doses (>4 g) due to saturation of hepatic glycine conjugation pathways (zero-order kinetics).
EXCRETION ROUTERenal — excretion of salicylic acid and its conjugated metabolites (salicyluric acid, salicyl acyl glucuronide, salicyl phenolic glucuronide) via glomerular filtration and active tubular secretion. The rate of renal clearance of free salicylic acid is highly dependent on urinary pH.
EXCRETION %~90% excreted in the urine as metabolites (primarily salicyluric acid) and free salicylic acid; ~10% excreted in feces or as other minor conjugates.
RENAL CLEARANCEHighly variable and urine pH-dependent. In acidic urine, free salicylic acid is extensively reabsorbed in the renal tubules. In alkaline urine (pH > 7.5), ion trapping occurs, and renal clearance of free salicylate increases dramatically, exceeding the glomerular filtration rate (GFR) — this principle is the foundation of urinary alkalinization in the treatment of salicylate overdose.
METABOLISMAspirin is rapidly hydrolyzed by esterases primarily in the gastrointestinal mucosa and liver (first-pass metabolism) to salicylic acid, which is the primary active circulating species. Salicylic acid is subsequently metabolized in the liver via Phase II conjugation pathways: primarily glycine conjugation (forming salicyluric acid, ~75%), phenolic glucuronidation (~15%), and acyl glucuronidation (~5%).
ACTIVE METABOLITESSalicylic acid — the primary active metabolite responsible for the majority of the systemic analgesic, antipyretic, and anti-inflammatory effects, as well as the dose-dependent toxicity. It has a longer, dose-dependent half-life compared to the parent aspirin molecule.
CYP ENZYMESAspirin and its primary metabolite, salicylic acid, are NOT metabolized by cytochrome P450 (CYP) enzymes. They do not inhibit or induce any CYP isoforms at therapeutic doses. The primary metabolic pathway is Phase II conjugation (glycine and glucuronic acid conjugation) in the liver and gastrointestinal mucosa. Therefore, aspirin has a very low potential for CYP-mediated pharmacokinetic drug-drug interactions.
TISSUE DISTRIBUTION & DIALYSIS CLEARANCE🧠 BBB: Crosses🤰 Placenta: Crosses🍼 Breast Milk: Excreted🧪 Dialyzable: Yes⚖️ Dose Adjustment: Required in Impairment
Aspirin is primarily cleared by the kidneys as salicylic acid and its conjugates. In patients with advanced chronic kidney disease (CKD), clearance is reduced, leading to systemic accumulation of salicylates and an increased risk of tinnitus and gastrointestinal bleeding. Furthermore, aspirin inhibits renal vasodilatory prostaglandins (PGE2, PGI2), which can precipitate acute kidney injury (AKI) or worsen hypertension in volume-depleted patients or those with pre-existing renal artery stenosis or heart failure. Low-dose aspirin (81 mg) is generally considered safe in stable CKD, but high-dose analgesic use should be avoided.
Aspirin should be used with extreme caution or avoided in patients with severe hepatic impairment or cirrhosis. The liver is the primary site of salicylate metabolism and the synthesis of vitamin K-dependent clotting factors. Hepatic dysfunction prolongs the half-life of salicylates and synergizes with aspirin's antiplatelet effect and gastric toxicity to create an unacceptably high risk of catastrophic gastrointestinal or variceal hemorrhage. Additionally, high-dose salicylates can cause direct, reversible hepatotoxicity (salicylate hepatitis), particularly in patients with juvenile idiopathic arthritis or systemic lupus erythematosus.